PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33838899-11	2021	Dinaciclib-AZD5153 combination therapy can be effective against MYCN-amplified and TERT-overexpressing neuroblastoma tumors.	AZD5153	11-18	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	64-68	
34693628-9	2022	CONCLUSIONS: We suggest that AZD5153, a novel dual-BRD4 inhibitor, can reduce MYCN levels in both anaplastic and nonanaplastic Wilms tumor cell lines, reduces tumor volume in Wilms tumor PDXs, and should be further explored for its therapeutic potential.	AZD5153	29-36	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	78-82